Head of Translation
Emmanuelle returned to the Sanger institute in 2022 to lead its translation function, striving to apply the extraordinary scientific outputs of this genomic research powerhouse towards new products and services that benefit society.
Prior to this role Emmanuelle built her business development career over fifteen years at very diverse organisations. Driven by developing and partnering early innovation in the life sciences, Emmanuelle held positions of increasing seniority at the Babraham Research Campus, the global charitable foundation Wellcome, the Sanger Institute and at Harness Therapeutics an innovative VC-funded therapeutic platform company.
Following on building a successful commercial strategy for COSMIC, the gold standard cancer mutations knowledgebase, Emmanuelle now chairs its Governance Board. She is also a Trustee for the Brain for Dementia Research, a rich longitudinal data and samples resource initiative funded the Alzheimer’s Society and Alzheimer’s Research UK, and a Non-Executive Director of two Sanger spinouts.
With an interest in sharing good practices in the translation of biodata, and building networks and communities, Emmanuelle has founded the Commercialisation of Genomic Research Courses.
She obtained her PhD at the Pasteur Institute in Paris in the field of anti-viral immunology.